

Rubella

SUBGAM (HUMAN NORMAL IMMUNOGLOBULIN (HNIG)
(Gammaglobulin for subcutaneous or intramuscular injection) 750mg.

Dispensed in vials of: - 750mg (approximately 5ml) - supplied by BPL

Indications

For use in pregnant women ONLY

The management of primary rubella or symptomatic rubella re-infection would depend on the gestation of pregnancy at which rubella occurred, and the individual circumstances of the women.

Risk of intrauterine transmission by gestational age

<11 weeks	90%
11-16 weeks	20%
16-20 weeks	Minimal risk of deafness only
>20 weeks	No increased risk

Dosage

750mg by intramuscular injection

Notes:

1. If large total doses (>5mls) of intramuscular HNIG are required, it is advisable to administer them in divided doses at different sites.
2. Post exposure prophylaxis with HNIG should be used when termination of pregnancy for proved rubella infection is unacceptable to the non-immune pregnant woman.
3. HNIG does not prevent infection in non-immune contacts but may reduce the likelihood of clinical symptoms, which may possibly reduce the risk to the foetus.
4. Neither MMR nor rubella vaccine are effective when given for post-exposure prophylaxis.
5. For further information see the HPA webpage "Rashes in pregnancy - HPA guidelines, information and advice" available at:
http://www.hpa.org.uk/infections/topics_az/pregnancy/rashes/default.htm